2 ASX 200 shares tipped by brokers to return 73% and 83%

Do you have either of these ASX 200 shares in your investment portfolio?

The S&P/ASX 200 Index (ASX: XJO) has fallen lower in Tuesday afternoon trade off the back of surging oil prices and investor concerns about potential interest rate increases.

At the time of writing, the ASX 200 is down around 1% for the day, and is now roughly 2% lower than 12 months ago.

But brokers have pinpointed some ASX 200 shares that could help lift the index over the next year. Here are two of them, and they're forecast to return up to 83% to investors.

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.

Image source: Getty Images

NextDC Ltd (ASX: NXT)

NextDC operates data centres in Australia, New Zealand, and Southeast Asia. The company builds and operates secure facilities where businesses can house their servers and IT equipment. 

It has physical centres, cooling, power, security services, and project support. And as data usage explodes, demand for secure, high-quality infrastructure is likely to grow alongside it.

The company is also investing heavily in expanding its business, with plans to accelerate the development of new facilities and expand existing sites, including its Sydney projects. 

Just last week, the company confirmed it had secured a $1.1 billion funding boost to support its growth plans.

The company will also be added to the S&P/ASX 50 Index (ASX: XFL) as part of a quarterly rebalance, effective from the 21st of September.

Late last month, the company also reported a record FY26 result, including a 16% increase in total revenue, a 16% increase in net revenue, and a 15% increase in underlying EBITDA. Net revenue and underlying EBITDA figures came in above guidance.

For FY27, NextDC has guided net revenue between $615 million and $640 million and underlying EBITDA between $385 million and $410 million, representing expected growth of over 50%.

Brokers are very bullish about the outlook for the ASX 200 shares over the next 12 months. Market Index data shows all brokers have a strong buy rating on the stock, and the $20.79 average target price implies a potential upside of 83% at the time of writing.

Mesoblast Ltd (ASX: MSB)

The clinical-stage ASX biotech company has had a slow start to 2026 but leapt higher in mid-July. The shares have slumped again over the past month, seemingly on the back of increased investor caution around clinical timelines and profit-taking following the mid-year rally.

Late last month, the company reported a sharp increase in revenue to US$120.3 million for FY26 (up from US$17.2 million in FY25) and a 44% reduction in net loss to US$57.5 million.

But there are opportunities for robust growth going forward. Mesoblast develops and commercialises allogeneic cellular medicines to treat complex diseases. Some products are already in use, and other cell therapies are in the late stages of clinical trials. 

Some of its products, particularly Mesoblast's Ryoncil, are gaining traction, and the business is well funded. 

Looking ahead, Mesoblast said it plans to expand its Ryoncil label to adults with severe SR-aGvHD and further advance development for chronic low back pain using rexlemestrocel-L. 

The company is also planning to develop next-generation cell therapies through new CAR-MSC and oncolytic virus technologies, broadening its pipeline for inflammatory and immunological diseases.

Brokers are also bullish that business growth and sales can continue growing strongly in FY27. Market Index data shows all brokers agree on a strong buy rating for the ASX 200 shares. The $3.60 average target price implies a potential 73% upside, at the time of writing. 

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »